BIOSTATISTICS IN CLINICAL TRIALS
Kate Francis, Biostatistician (Snr Research Officer)
Murdoch Children’s Research Institute &
Honorary Research Fellow,
Department of Paediatrics, University of Melbourne &
Affiliate Biostatistician,
The Royal Children’s Hospital,
Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | July 2025
Kate Francis is a biostatistician with the Murdoch Children’s Research Institute (MCRI), an Honorary (Senior Fellow) within Department of Paediatrics, the University of Melbourne and Affiliate biostatistician with Royal Children’s Hospital in Narrm (Melbourne), Australia.
As a biostatistician working in research and clinical settings, she plays a vital role in ensuring all projects adhere to best practice guidelines and are transparently reported. She has served as the lead statistician for the analysis of clinical trials across a broad range of subject areas, including neonatal resuscitation, BCG for allergy and infection, convulsive status epilepticus and her work has been published in the top journals such as The New England Journal of Medicine, JAMA, and The Lancet. Most recently she was awarded the 2025 Excellence in Trial Statistics Award for her work on the PLUSS trial.
Kate is also an expert in the measurement of adolescent health behaviours, determinants, and outcomes and this was recognised with her invitation to be a commissioner for the second Lancet Commission on Adolescent Health and Wellbeing which was recently released at the 2025 World Health Assembly meeting.
Kate believes in the importance of gender equity, diversity, and inclusion and was key team member in helping MCRI achieve bronze accreditation in the Science in Australia Gender Equity (SAGE) program.
Source: Supplied
You Might also like
-
Anne O’Neill
STATE GOVERNMENT SUPPORTING MEDICAL RESEARCH
@ NSW HEALTH, NEW SOUTH WALES AUSTRALIA -
Investigating the benefits of donor human milk for preterm infants
Together, SAHMRI and Lifeblood are leading a consortium to revolutionise the way human milk, and novel products made from human milk, are used as nutritional and medical interventions to improve health outcomes in vulnerable infants, but with potential application for a diverse range of medical indications.
Currently, babies who are born early preterm – before 32 weeks – are given donor milk when their own mother’s milk is not available or in short supply. Whether donor milk is beneficial for babies born just a few weeks early is unclear, as very little research has been undertaken with these babies.
The GIFT Trial will soon commence as an investigation between SAHMRI, the University of Adelaide, the Red Cross Lifeblood Milk Bank conducted at five sites across three states in Australia.
-
Nutraceutical and pharmacological intervention in neurological disorders
Dr Virginie Lam is a neuroscientist and cerebrovascular biologist with over 15 years of research experience, including more than seven years post-PhD. She co-leads the Neurovascular and Metabolic Diseases Laboratory at the Curtin Medical Research Institute and holds an affiliate appointment at the Perron Institute for Neurological and Translational Science. Her research focuses on the interface between neurovascular health, cognitive function, and therapeutic translation in neurodegenerative disorders.